THE MODERN LIVING PEACE TRAIN™
Checking your passage…
One moment while your discovery opens.
Pancreatic cancer: essential context
Sources and review scope
These source notes explain the evidence consulted and its limits. Educational information does not replace individual medical care.
- PA-DEF
- NCI: What is pancreatic cancer?
Location; exocrine and endocrine tumor distinction; ductal adenocarcinoma · Selected supporting text read on 11 November 2026 (UTC). Source verification is distinct from independent clinical appraisal.
Used for cancer location and cell types. For the distinction between digestive enzymes and endocrine hormones, consult the separate SEER anatomy reference.
- PA-SEER
- NCI SEER: Pancreatic and biliary tract anatomy
Endocrine hormones regulating blood sugar; exocrine enzymes entering duodenum · Selected supporting text read on 11 November 2026 (UTC). Source verification is distinct from independent clinical appraisal.
Selected official educational sections, not a complete clinical evidence appraisal or a personal treatment recommendation.
- PA-CARE
- NCI: Pancreatic cancer treatment
Treatment planning; surgery; digestive enzymes; molecular testing; palliative care · Selected supporting text read on 11 November 2026 (UTC). Source verification is distinct from independent clinical appraisal.
Selected care context only. Full drug labels, comparative regimens, trial protocols and numerical efficacy are not appraised here.
- PA-NHS
- NHS: Pancreatic cancer symptoms
Symptoms; changed digestive symptoms; urgent advice · Selected supporting text read on 11 November 2026 (UTC). Source verification is distinct from independent clinical appraisal.
Publisher review date is past due; that is not relabeled as a new review. Targeted symptom text remains accessible.
- PA-FDA
- FDA: Rasonque pancreatic cancer approval
26 August 2026 approval; population; randomized trial description; common harms · Selected supporting text read on 11 November 2026 (UTC). Source verification is distinct from independent clinical appraisal.
Approval announcement only, not full prescribing information or a complete trial appraisal. This page provides neither dosing, numerical efficacy estimates nor individual eligibility decisions.
- C-INF
- NCI: Infection during cancer treatment
Infection signs; urgent contact; fever-masking medicines · Selected supporting text read on 11 November 2026 (UTC). Source verification is distinct from independent clinical appraisal.
Reuses targeted text read earlier on 11 November. Older official safety education; individual oncology emergency instructions take priority.
- C-NUT
- NCI: Nutrition during cancer treatment
Nutrition assessment; meal preparation; treatment-related eating difficulties · Selected supporting text read on 11 November 2026 (UTC). Source verification is distinct from independent clinical appraisal.
Reuses targeted text read earlier on 11 November. Food support is not a cancer therapy; no universal nutrient or supplement prescription.
